used as one of the most potent agents to study the role of gut microbiota (Jernberg et al., 2010) . 70 Because of frequent and long term usage, various commonly used antibiotics can change the 71 composition, diversity, and richness of commensal gut microbiota to result in alteration of 72 different metabolism of the host (Dethlefsen et al., 2008; Fujisaka et al., 2016) and may lead to 73 different metabolic syndromes like diabetes, obesity, and Inflammatory Bowel Disease (Bosi et 74 al., 2006; Dunlop et al., 2006) . Intensity of the perturbation of commensal microbes, by 75 antibiotics, depends on different factors like a) the mode of action of a particular antibiotic and 76 b) the presence of various resistant group of microbes in gut against the antibiotic (Jernberg et  77 al., 2010). 78
Among various antibiotics, vancomycin is majorly prescribed orally against the infection of two 79 multi-drug resistant strains; i.e., Clostridium difficile and Staphylococcus (Bernard et al., 2003; 80 Pepin, 2008; Tang et al., 2015) . Besides the effectiveness of vancomycin in Clostridium Difficile 81
Infection (CDI) patients, it can cause drastic changes in the human gut microbiota by increasing 82 pathogens and decreasing the commensal healthy microbes (Isaac et al., 2016) . It has also been 83 reported that following treatment with vancomycin in humans for 7 days, genes for oxidative 84 pathways were upregulated and the genes for immune pathways were downregulated (Reijnders 85 et al., 2016). 86 However, the dose and time dependent effects of vancomycin on gut microbiota are still 87
unknown. The present study focuses on the effect of a clinical dose of vancomycin on mouse gut 88 microbiota and its effect on different physiology of mice. The current study reveals that the 89 changes, that happen in gut microbiota following treatment of mice with vancomycin, are not as 90 evident as reported before. Although initially, vancomycin treatment causes an increase in 91 abundance of specific pathogens and a decrease in native microbes, but at the later stage of the 92 treatment, some healthy microbes start appearing and pathogens started declining, that could 93 provide health benefits to the host. 94 The current laboratory reported earlier the effects of probiotics on the gut microbiota of Th1 and 95
Th2 biased mice (Pradhan et al., 2018). There are reports that elucidated the intrinsic differences 96 in immune and immune-metabolic responses between C57BL/6 (Th1) and BALB/c (Th2) mice 97 (Jovicic et al., 2015; Watanabe et al., 2004) , we reported the differences in gut microbiota from 98 phylum to genus between the two strains (Th1-and Th2-biased mice) (Pradhan et al., 2018) . In 99 the current study, we reported the role of vancomycin on gut microbiota in Th1 and Th2 mice. 100
The microbiota present in the gastrointestinal tract is important for the development of a mature 101 immune system of the host (Hooper et al., 2012) . It has been reported that the gut microbiota 102 influences the immune system of the host through interaction of their molecular patterns 103 (lipopolysaccharide, peptidoglycan) with toll-like receptors (TLR4, TLR2) present in the 104 epithelial cell of the gut. This interaction produces various cytokines and chemokines for 105 immune regulation (Christiansen et al., 2018) . In this study, following vancomycin treatment, we 106 observed and correlated the kinetics of immunological changes of host at both transcriptional and 107 protein level with metagenomic changes in the gut of C57BL/6 and BALB/c mice. 108
Microbiota present in the gut controls the metabolism of major nutrients like carbohydrates, 109 amino acids, fatty acids, and vitamins. Moreover, it was already reported that some microbes 110 could convert complex carbohydrates into short chain fatty acids (SCFAs) like acetate, 111
propionate, and butyrate, and these SCFAs play important roles in regulating inflammatory 112 response and metabolism of the host by binding to free fatty acid receptors (e.g. FFAR2/3) 113 present in intestinal epithelial cells, immune cells, adipocytes (Morrison and Preston, 2016) . 114
Intestinal epithelium acts as a barrier to the entry of different pathogens, inflammatory molecules 115 and toxins into the mucosal tissue (Turner, 2009 ). The commensal microbes present on intestinal 116 epithelial cell maintain the integrity of the gut permeability by controlling the expression of 117 various tight junction proteins such as by occludin, claudin, and mucin (Ulluwishewa et al., 118 2011). The defects in barrier due to perturbation of gut microbiota leads to different metabolic 119 diseases like Inflammatory Bowel Disease, obesity, and diabetes (Bosi et al., 2006; Dunlop et al., 120 2006 ). In the current study, we reported that the variation in the abundance and diversity of 121 different groups of microbes, in Th1 and Th2 mice, could differentially regulate the gut barrier 122 integrity, host inflammation and glucose tolerance. 123
Material and methods: 124
Animal Used in study: All mice of same strain used in the present study were co-housed in 125 polysulfone cage, and corncob was used as bedding material. Food and water were provided ad 126 libidum. Animals were co-housed in a pathogen-free environment with 12h light-dark cycle 127 (lights on from 7:00 am -7:00 pm), at temperature 24 ± 3° with the humidity around 55%. 128
Guidelines Zhou and Zhi, 2016). Alignment of these representative sequences against reference chimeric 209 data sets was done and RDP classifier against SILVA database was used for taxonomic 210 classification to get rid of hybrid sequences. 211
CMT (cecal microbiota transplantation): Cecal sample was collected from sixth day 212 vancomycin treated mice and diluted with PBS (1gm/10ml) to make stock. 400 µl of the stock of 213 cecal material was orally gavaged to each of third day vancomycin treated mice. 214
Glucose tolerance test (GTT): GTT was assayed on days 0, 3 and 6 following treatment of both 215 types of mice with vancomycin. Following 6h of starvation of mice from each treatment group, 216
fasting blood glucose level (considered as control glucose level at 0 minute) was measured by a 217 glucometer by tail vein bleeding. Mice, fasted for 6h, were orally gavaged with glucose at a dose 218 of 1 mg/g body weight of mouse. Blood glucose levels were measured at intervals of 15-, 30-, 219 60-and 90-minutes post-glucose gavaging by using blood glucose monitoring system (ACCU-220 CHEK Active, Roche Diabetes Care GmbH, Mannheim, Germany). 221
Same procedure was adopted for oral glucose tolerance test was done for third day CMT 222 recipient mice following 24h of CMT procedure. 223
Sample preparation and NMR data acquisition for metabolomics study 224
Serum was isolated from blood of vancomycin treated and control mice as described before. 225
Proteins in the serum were removed by passing it through pre-rinsed (7 times washed) Amicon 226
Ultra isoflurane inhalation and blood was collected by cardiac puncture. Serum was collected from 252 blood and concentration of FITC in serum was measured by spectro-fluorometry with an 253 excitation wavelength of 485 nm (20 nm bandwidth) and emission of 528 nm (20 nm bandwidth) 254 (Woting and Blaut, 2018) . 255
Endotoxin detection assay from serum: Mice were sacrificed on days 0, 3 and 6 following 256 treatment of mice with vancomycin and blood was collected by cardiac puncture in an 257 endotoxin-free vial. Toxinsensor chromogenic LAL endotoxin assay kit from GeneScript 258 (Cat#L00350, Piscataway, NJ, USA) was used for detecting endotoxin level in serum of mice 259 using the manufacturer's protocol. 260
Acetate detection assay in serum: Acetate level was measured in the serum samples of 261 untreated (control day 0) and day 6 following treatment of BALB/c and C57BL/6 mice with 262 vancomycin by using acetate colorimetric assay kit (EOAC-100, San Francisco, USA). Both 263 control and treated mice were anesthetized and blood was collected through cardiac puncture. 264
Blood was kept on ice for 30 mins followed by centrifugation at 1700 rpm for 15 min at 4 °C. 265
The supernatant was collected and 10 µl of serum from each sample was used to detect acetate 266 level and after substrate-enzyme coupled reaction formed color, absorbance was taken at 570 267 nm. 268
Hormonal assay: Leptin (Cat# ELM-Leptin), and Insulin (Cat# ELM-Insulin) hormone levels 269
were assayed in serum samples and PYY (Cat# EIAM-PYY) in gut tissue samples for both 270 mouse strains (BALB/c and C57BL/6) on day 3 and day 6 following treatment with vancomycin 271 and compared with untreated day 0 control mice by using Raybiotech mouse hormonal assay kit 272 (Norcross, Georgia, USA). 273
Statistical Analysis 274
All the graphs were plotted using GraphPad Prism 7.0a. Statistical package in Prism was used for 275 statistical analysis for the data to perform 't'-test (to compare any 2 data sets) or ANOVA (to 276 compare more than two datasets) as described in the text. that Proteobacteria level in vancomycin treated mice increased from 1-2% (with respect to no 287 treatment group) to 90% (on day 4 following treatment with vancomycin). On the contrary, 288
Firmicutes level decreased from 70-80% (untreated group) to below 10% (fourth day following 289 treatment with vancomycin) and Bacteroidetes level from 25-30 % (untreated group) to 1% 290 (fourth day following treatment with vancomycin) (Figs 1B and 1D). 291
In addition, we further determined the diversity of the cecal microbiota. Shannon equitability 292 index for diversity at phylum level showed a decrease in diversity up to the fifth day of treatment 293 in BALB/c ( Fig.1E ) and fourth day of treatment in C57BL/6 mice ( Fig.1F ). Diversity increased 294 on day 6 for BALB/c and day 5 for C57BL/6 following treatment with vancomycin. Changes in 295 abundance and diversity in cecal microbiota opened up avenues for newer explorations some of 296 which is reported here later. 297
Comparative analysis of time dependent changes in genus level data in time matched BALB/c 298 and C57BL/6 specific controls ( Fig. 2A and Fig. 2C ) and in vancomycin treated BALB/c and 299 C57BL/6 (Figs 2B and 2D) further corroborated with phylum level results ( Fig. 1 ). When 300
Shannon equitability index for measuring diversity between phylum and genus level data were 301 compared, it was observed that the trend of the data at both levels until day 5 were similar but 302 absolute values were different (Table 1) . Day 6 values for phylum and genus were similar for 303 either BALB/c or C57BL/6 ( inflammation (Holzheimer, 2014) . It is also important to note that the Firmicutes (F) from 60-309 70% and Bacteroidetes (B) from 30-35% on day zero turned to 10% (F) and 1% or less for B for 310
both BALB/c and C57BL/6 on day 5 or day 4, respectively. This suggested increase in 311
Firmicutes/Bacteroidetes (F/B) ratio is correlated with enhanced body mass index and 312
inflammation (Koliada et al., 2017) . Current results showed increase in F/B ratio of 2-fold on day 313 0 to 10 fold or more following treatment with vancomycin on day 5 for BALB/c or day 4 for 314 C57BL/6. The F/B ratio significantly decreased after day 4 or 5 for C57BL/6 or BALB/c. It is 315
further observed that the phylum, Verrucomicrobia level increased (20-25%) in BALB/c mouse 316 (Fig. 1D ) on the sixth day following treatment with vancomycin and Verrucomicrobia increased 317 significantly (>80%) from fifth day following vancomycin treatment in C57BL/6 mice ( Fig. 1F ). 318
Akkermansia genus from Verrucomicrobia phylum increased from 2-3% (untreated group) to 70-319 75% by fifth day following treatment with vancomycin in C57BL/6 mice ( Fig. 2D ). This result is 320 significant to understand the differential response exhibited in two different mice species 321 (C57BL/6 and BALB/c) used in this study following treatment with vancomycin. The 322 differences observed may be because of the immune bias (Th1 and Th2) of two species leading 323
to different beneficial effects of Akkermansia to regulate glucose tolerance efficiency. 324 It is reported that Akkermansia muciniphila in the Verrucomicrobia phylum is the major known 325 species that contributes positively to enhance insulin sensitivity and glucose metabolism by 326 reducing inflammation and body-weight gain (Cani and de Vos, 2017; FUJISAKA et al., 2018; 327 Khan et al., 2014) . We, therefore, tested for A. muciniphila on day 6 following treatment with 328 vancomycin of BALB/c and C57Bl/6. Species specific primer (Table 2) of Akkermansia 329 muciniphila was used to confirm its abundance (Collado et al., 2007) . Results revealed that there 330 was a 6-fold increase in A. muciniphila abundance in vancomycin treated BALB/c on day 6 331 compared to time matched untreated control while the abundance of A. muciniphila was around 332
16384-fold and 24833-fold higher in vancomycin treated C57BL/6 on day 5 and day 6 compared 333 to its time matched control. The current study revealed a hitherto unknown fact that abundance 334 of A. muciniphila increases significantly following treatment with Vancomycin. The increase of 335
A. muciniphila may have beneficial roles in physiology. 336
The inflammatory response in gut changes during vancomycin treatment in terms of 337 dosage and with time 338
Pro-and anti-inflammatory responses are two important classes to check out the outcome of 339 various treatments. Current results revealed that expression of pro-inflammatory cytokine genes 340
(tnfα, il6, il1a, il17) in the gut at transcriptional level, increased till day 5 for BALB/c mice ( Fig.  341 3A) and till day 4 for C57BL/6 mice ( Fig. 3B ) following treatment with vancomycin. 342
Concentration of anti-inflammatory cytokines (tgfb, and il10) started increasing and pro-343
inflammatory cytokines started decreasing from day 6 in BALB/c mice ( Fig. 3C ) and from day 5 344 in C57BL/6 mice ( Fig. 3D ) following treatment with vancomycin. Concomitant to the increase in 345 pro-inflammatory cytokines we observed increase in expression of tlr4 at transcriptional level till 346 day 4 and tlr2 till day 6 in both BALB/C and C57BL/6 mice following treatment with 347 vancomycin ( Fig. 3E and Fig. 3F ). 348
Major changes happened in the expression of tnfα and il10 at the transcriptional level, as 349 revealed from qRT PCR data, on day 3 and day 6 following treatment with vancomycin in both 350
Th1-and Th2-mice. Validation of qRT PCR results was done, at the protein level expression of 351 gut wall tissues, by ELISA ( Fig. 4) . ELISA results revealed that, on the third day following 352 vancomycin treatment, TNFα level was significantly more in both BALB/C ( Fig. 4A ) and 353 C57BL/6 ( Fig. 4B ) mice with respect to day 3 time-matched untreated control group of mice. 354 Similarly, IL10 cytokine level was more in BALB/c ( Fig. 4C ) and C57BL/6 ( Fig.4D) Gut permeability increased following vancomycin treatment: 367
Gut permeability gets affected as a direct consequence of altered gut microbiota. Alteration of 368 abundance and diversity of gut microbiota is measured in terms of the cecal index of host (a 369 measure of normalized cecal mass over body mass). The cecal index was calculated and the ratio 370 was significantly more in vancomycin treated C57BL/6 and BALB/c mice than their respective 371 time-matched control groups (Fig. 5A ). Cecum is known to be a better representation than fecal 372 sample for understanding intestinal microbiota profile (Donaldson et al., 2016) and cecum 373 usually gets enlarged following treatment with antibiotic by accumulating fluid and solid matter 374 (Reikvam et al., 2011). The changes in the bacterial composition due to antibiotic treatment in 375 cecum may have led to accumulation of significantly high volume of fluid in its lumen. The fluid 376 volume following centrifugation of cecal sample was significantly more in vancomycin treated 377 mice than respective time-matched control mice (Fig. 5B ). In vancomycin treated mice, a larger 378 cecum with more fluid accumulation was observed than control mice (Fig. 5C ). For further 379 confirmation of gut permeability, FITC conjugated dextran was gavaged on day 3 following 380 treatment with vancomycin and in respective control mice. FITC dextran Concentration was 381 detected significantly higher in the serum of mice on day 3 following vancomycin treatment 382 (BALB/c 341.6±25.9 ng/ml, C57BL/6 367.5±25.3 ng/ml) than corresponding time-matched 383 control mice (BALB/c 217.1±24 ng/ml, C57BL/6 229.8±22 ng/ml). (Fig. 5D ). The preceding 384 observations on fluid accumulation and FITC-dextran results on gut permeability prompted us to 385 check for respective gene expression. The results from qRT-PCR revealed compromised 386 expression of tight junction genes (occludin and claudin) at transcriptional level in the gut of 387 vancomycin treated mice at different time point with respect to the time-matched control mice. 388
Their expression of claudin gene decreased continuously from day one to day six following 389 P a g e | 1 0 treatment with vancomycin in BALB/c (from 1.2-fold activation following vancomycin 390 treatment with respect to time matched control on day zero to 3.4-fold repression on day 6 by 391 treatment with vancomycin when compared to time matched untreated control) and C57BL/6 392 (From two-fold activation on day zero to 1.5-fold repression on day six when vancomycin 393 treated mice re compared to untreated time matched controls) mice ( Fig. 5E and Fig. 5F ). 394 Similarly, expression of occludin gene decreased in BALB/c mice (from 2.5-fold activation on 395 day zero to 6.5-fold repression on day six) and C57BL/6 (from 2.3-fold activation on day one to 396 no-change on day six) following vancomycin treatment. It is important to note that the 397 expression of claudin 1in C57BL/6 and occludin in both C57BL/6 and BALB/c mice, that were 398 activated on day 1 following vancomycin treatment but significantly repressed following 399 treatment with vancomycin on subsequent days. The results presented in Figs. 5E and 5F, 400
perhaps suggested that effects of vancomycin on expression of gut permeable genes are very 401 rapid. The results of gene expression corroborated with the FITC-dextran data to confirm 402 reduced gut permeability following vancomycin treatment in both C57BL/6-and BALB/c mice. 403
While results from FITC dextran studies on day 6 suggested restoration of gut barrier for both 404 BALB/c and C57BL/6 expression of claudin 1 and occludin genes remained repressed with 405 respect to time matched control mice. Further studies are required to understand this apparent 406 discrepancy which may be due to a different mechanism, independent of these two genes, that 407 may exist to re-establish the gut barrier function. 408
The reduced gut permeability following treatment with vancomycin may lead to increased level 409 of systemic endotoxin level. The endotoxin level in serum correlates with increase in pathogenic 410 gram-negative bacteria (proteobacteria) in gut and compromised permeability and inflammation 411 of gut tissue (Holzheimer, 2014) . The endotoxin level was measured in the serum of control and 412 vancomycin treated mice. On the third day of vancomycin treatment, endotoxin level was the 413 highest in the serum of both BALB/c (0.82±0.07 EU/ml) and C57BL/6 (0.67±0.12 EU/ml) mice 414 but on the sixth day, its level decreased (0.44±0.07 EU/ml in BALB/c and 0.16±0.05 EU/ml in 415 C57BL/6 mice) and became similar with the control group of mice (Fig.5G) . The results may be 416 corroborating with either enhanced level of beneficial bacteria on day 6 following vancomycin 417 treatment as described below or due to decreased level of proteobacteria or both. 418
Alteration of blood glucose level with changes in Proteobacteria and Verrucomicrobia level 419 in gut: 420
Glucose is an important metabolite to keep the energy requirement and balance in the body. It is 421 also easy to measure in the host blood to determine the glucose metabolism status. Kinetics of 422 oral glucose tolerance test (OGTT) from 0 to 90 minutes was done following 12h fasting of 423 either strain of mice. From glucose tolerance test, it was revealed that glucose metabolism was 424 different in control and vancomycin treated mice ( Fig. 6A and 6B ). Important to note that the 425 results from OGTT studies for control animals for both BALB/c and C57BL/6 remain unchanged 426 on days 0, 3 and 6. On the day 3 following vancomycin treatment, fasting serum glucose levels 427 in the Th2-and The metabolism rate of glucose in the blood of the sixth day vancomycin treated mice (VB6, 437 VC6) was faster than the third day treated mice (VB3 and VC3). This rate was higher for VC6 438 than VB6. In VC6 group of mice, the glucose level in the blood came to normal rapidly and its 439 concentration at ninety-minute post glucose gavage was similar with the control group in 440 BALB/C mice and lower than the control group in C57BL/6 mice. In VB3 and VC3 group of 441 mice, the glucose concentration in blood at ninety minutes was still higher than control. 442
Day 3 vancomycin treated mice were transplanted with cecal microbiota (CMT) of day 6 443 vancomycin treated mice (more abundant with A. muciniphila) to observe its efficacy on glucose 444 metabolism. In CMT treated group of day 3 (following vancomycin treatment) mice, glucose 445 level in serum decreases drastically in C57BL/6 mice ( Fig. 6B ) and became equivalent to control 446 groups of mice but in BALB/c mice the effect was insignificant (Fig. 6A ). 447
Metabolite level in serum changes following vancomycin treatment 448
It is believed that the short chain fatty acids (SCFA) are the microbes associated molecular 449 patterns that could regulate innate immunity of the host. The current results revealed that the 450 ratio of abundance of acetate/lysine (Fig. 6C ), butyrate/lysine ( Fig. 6D ) and propionate 451 /threonine ( Fig. 6E) were lower but their respective substrate concentrations (lysine, and threonine) were higher than 457 control on day 6 post vancomycin treatment. Important to note here that concomitant with the 458 Th1-(C57BL/6) and Th2-(BALB/c) bias of the mice one should expect lower level of abundance 459
of SCFAs in control (untreated) C57Bl/6 (CC) and control BALB/c (CB) on day 0 and our 460 results supported such proposition ( (Fig. 6F ). 471
The results implied for the first time the role of vancomycin on SCFA production in Th1-and 472
Th2-biased mice. Results also supported the intrinsic SCFA production (more in Th2-compared 473
to Th1-biased mice) as per the immune bias of mice strain. 474
Gut hormonal level during vancomycin treatment 475 We already reported the rate of glucose metabolism that increased and production of SCFAs that 476 decreased on day 6 following treatment with vancomycin. Considering the changes in glucose 477
and SCFAs we investigated further the roles of other associated hormones such as insulin and Results (Fig. 7A ) revealed that the concentration of insulin in serum on the third day of 481 P a g e | 1 2 vancomycin treated a) BALB/c (VB3) was 1.16±0.25 ng/ml and b) C57BL/6 (VC3) was 482 1.43±0.15 ng/ml. Similarly, the concentration of insulin in serum on the sixth day of vancomycin 483 treated a) BALB/c (VB6) was 0.98±0.1 ng/ml and b) C57BL/6 (VC6) was 0.83±0.06 ng/ml. Fig.  484 7A revealed that insulin level decreased significantly on day 6 compared to day 3 following 485 treatment with vancomycin for both BALB/c and C57BL/6. However, insulin levels for both 486 mice strains on day 3 and day 6 post-vancomycin were significantly higher than day 0 (untreated 487 controls CB and CC). As hypothesized, no significant changes were observed in serum leptin 488 concentrations on any day following vancomycin treatment of BALB/c and C57BL/6 mice with 489 respect to respective untreated controls (Fig. 7B) . The results revealed that the concentration of 490 PYY hormone in the gut decreased following vancomycin treatment in BALB/c (8836±311 491 pg/mg of tissue on day 0 and 4843.9±149 on day 6) and in C57BL/6 mice (7883±155pg/mg of 492 tissue on day 0 to 6283.8±209 on day 6) ( Fig.7C) . As documented recently that SCFA regulates 493 PYY production is validated by the current results (Larraufie et al., 2018) . Vancomycin 494 treatment reduces SCFA level following deceased abundance of PYY. 495 496
Discussion 497
The extent of perturbation of gut microbiota varies differently following treatment with different 498 antibiotics. We selected vancomycin for continued studies, because metagenomic (16S rRNA) 499
analysis of cecal samples of mice showed that vancomycin altered the gut microbiota most 500 extensively by decreasing the phylum like Firmicutes and Bacteroidetes and by increasing the 501 Proteobacteria level. As described before the dosage of vancomycin used was as per FDA 502 guidance. By correlating the NGS data with plating data, it might be concluded that the group of 503 bacteria, that overpopulated on the plate following day 2 but decreased following day 5 of 504 vancomycin treatment, might belong to Proteobacteria phylum. Proposition was further 505 validated by plating the cecal samples of day 3 vancomycin treated mice on specific media such 506 as, salmonella-shigella specific agar plate and EMB agar plate. Results from media specific 507 growth suggested overgrown colonies were mostly Shigella and E.coli and it was proven by 508 metagenomic data of cecal samples at genus level. Metagenomic analysis further suggested that 509 following day 5 and day 6 treatment with vancomycin, Verrucomicrobia phylum replaced the 510
Proteobacteria phylum in the gut. The Verrucomicrobia phylum consists of Akkermansia genus 511 that is showing promise for future therapeutics and prophylaxis (Maier et al., 2014) . 512
During vancomycin treatment, Proteobacteria phylum started increasing significantly up to day 4 513 post-vancomycin treatment and it replaced other phyla like Firmicutes, Bacteroidetes, 514
Actinobacteria, Tenericutes, and Verrucomicrobia (Figs. 1D and 1F ). This increase in only one 515 phylum (Proteobacteria) caused decrease in the diversity of other gut microbiota; therefore, gut 516 microbiota diversity was the lowest on day 4 following treatment with vancomycin for C57BL/6 517 and on day 5 following treatment with vancomycin for BALB/c mice. During treatment with 518 vancomycin till day 4, abundance of Proteobacteria was over 90% while abundance of other 519 phyla was significantly low. Starting from day 5 following treatment with vancomycin, 520
abundance of other phyla such as, Firmicutes, Tenericutes, and Verrucomicrobia started 521 increasing in the gut resulting into greater diversity that culminated on the sixth day of treatment 522 ( Fig. 1G and Fig. 1H ). 523
In Proteobacteria phylum, Escherichia and Shigella genera were increased in mice gut during 524 vancomycin treatment. These genera belong to gram-negative groups of bacteria containing LPS, 525 that increases the endotoxin level in blood. These bacteria activate the tlr4 receptor present in the 526 gut epithelial cell, and this increases the expression of pro-inflammatory cytokines. 527 following treatment with vancomycin. On the sixth day following vancomycin treatment, in 554 C57BL/6, replacement of Proteobaceria by Verrucomicrobia caused significant improvement in 555 glucose metabolism in mice; fasting glucose ( Fig.6A and 6B ) and insulin level (Fig. 7A ) in blood 556 came to normal. This effect is more prevalent in C57BL/6 than BALB/c mice. Following 557 successful transfer of cecal sample from sixth day of vancomycin treated C57BL/6 mice (A. 558 muciniphila level is above 70%) to third day of vancomycin treated mice, blood glucose level 559 decreased significantly on the third day mice, which showed the effective role of Akkermansia 560 muciniphila in controlling the blood glucose level. Higher fasting Insulin concentration in serum 561 of the third day vancomycin treated BALB/c and C57BL/6 than control and sixth day 562 vancomycin treated C57BL/6 mice (Fig.7A) showed the insulin resistance following vancomycin 563 treatment and its correlation with A. muciniphila level in mice gut. On the sixth day of 564 vancomycin treatment, A.muciniphila level is significantly higher than in C57BL/6 mice than 565 BALB/c, which might cause more prominent effect in decreasing glucose and insulin level in 566 blood of C57BL/6 mice than BALB/c mice ( Fig.6A and 6B) . 567
It is also important to note that the SCFA production was more in Th2-compared to Th1-biased 568 mice. More SCFA usually leads to anti-inflammatory response or Th2-bias. Current observation 569 further confirms the fact as per the immune bias of mice strain used. SCFA stimulates PYY 570 hormone production by activating Gq coupled receptor FFA2 of endocrine cells present in the 571 gut (Larraufie et al., 2018) . The current results revealed that following treatment with 572 vancomycin the level of SCFA decreased, which cause a reduction in serum PYY production 573 P a g e | 1 4 ( Fig.7C ) that might have an effect of observed enhanced glucose metabolism or increased insulin 574 sensitivity (Cahill et al., 2014) . We observed decrease in insulin level in serum on day 6 was less 575 than day 3 following treatment with vancomycin but blood glucose level was better managed on 576 day 6 compared to day 3 perhaps suggesting enhanced insulin sensitivity. 577
The clinical dose of vancomycin treatment perturbs the gut microbiota of mice by depleting the 578 healthy microbes and increasing the proteobacteria group microbes that include various 579
pathogens. The increased proteobacteria, until day 3 following vancomycin treatment, could 580 disrupt the homestasis of various physiological processes (such as, immunological and 581 metabolic) and as a result it perhaps increased serum endotoxin level, blood glucose level, and 582 enhanced pro-inflammatory responses. Physiology, in terms of endotoxin, glucose or 583 inflammation status, got restored at the later stages of treatment (day 5 or 6). The restoration of 584 these physiological parameters may be because of decrease in harmful proteobacteria and 585 increase in certain type of healthy microbes like Verrucomicrobia. Generally, the 586
Verrucomicrobia phylum that appeared in huge number at the later stages of vancomycin 587 treatment are present very less number in control group, but their functional role is similar to a 588 major group of healthy microbes of the gut to restore the equilibrium by alleviating the adverse 589 effects of Proteobacteria. Proetobacteria belong to gram-negative groups of bacteria containing 590 LPS, that increases the endotoxin level in blood. These bacteria activate the tlr4 receptor present 591
in the gut epithelial cell, and this increases the expression of pro-inflammatory cytokines. 592
Combinatorial effect of the increase in Proteobacteria and decrease in Firmicutes in mice gut 593 caused the elevation in inflammation of the gut tissue. 594 595
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Contribution to the Field Statement 606
Anti-biotics play important role in our society in terms of regulating and maintaining our health. 607
Overuse of the antibiotics yielded a major threat and we are looking for better ways to alleviate 608 the problem of antibiotic resistance. Microbiota can provide the solution that is required along 609 the line. However, understanding the problems associated with antibiotic usage and the help that 610 could be conferred by the microbiota needs more studies. The current study is providing a small 611 leap in that direction by showing the usage of antibiotic like vancomycin that may boost certain 612 beneficial microbes that can confer genuine health benefits. The current study in 613 immunologically differently biased mice revealed that the treatment with vancomycin elevated 614 abundance of A. muciniphila may provide health related significant benefits more in mice with 615 proinflammatory (C57BL/6) bias over tolerogenic mice (BALB/c). To the best of our knowledge 616 the current report is the first of its kind where it is showing the importance of perturbation of gut 617 microbiota to exert on their roles and also how a treatment with an antibiotic may become 618 beneficial for health manipulation. 619 Glucose tolerance and abundance of select metabolites in serum. Kinetics of fasting blood sugar 901 in A. BALB/c B. C57BL/6 mice following treatment with Vancomycin on days 0, 3 and 6 and 902
following treatment with CMT from day 6 vancomycin treated mice transferred to vancomycin 903 treated day 3 group of mice. Ratio of abundance, from chemometric 1 H-NMR studies for major 904 short chain fatty acids, of C. acetate production over lysine, D. butyrate production over lysine 905 and E. propionate production over threonine in untreated control BALB/c (CB) and C57BL/6 906 (CC) and Vancomycin treated BALB/c (VB) and C57BL/6 (VC) are compared for Day 0 and 907 Day 6 following treatment with vancomycin. In addition, F. acetate concentration in the serum 908 by using acetate detection kit on day 6 in vancomycin treated groups of mice (VB6, VC6) along 909 with the time matched control mice (CB6, CC6) of BALB/c and C57BL/6, respectively. In the 910 figure, '***' corresponds to P ≤ 0.001, '**' corresponds to P ≤ 0.01, level of significance). 
